

# CLINIGEN FACTSHEET

## FINANCIAL PERFORMANCE FY21

ADJUSTED NET REVENUE (£M)

**458.6**

ADJUSTED EBITDA (£M)

**116.3**

ADJUSTED BASIC EARNINGS PER SHARE (PENCE)

**55.9**

## WHAT ARE OUR STRATEGIC OBJECTIVES?

Delivering the right medicine, to the right patient, at the right time.

- 1 ..... Cultivate a thriving high performance culture
- 2 ..... Drive operational excellence
- 3 ..... Partner with clients to deliver synergistic value
- 4 ..... Lead the market in customer experience
- 5 ..... Enhance portfolio of assets, services and territories
- 6 ..... Realise competitive advantage through technology

## TRUSTED GLOBAL PLATFORM

Clinigen exists to enable quicker and broader access to critical medicines around the world. Our global platform stretches across the pre & post-launch phases of a medicine's lifecycle, from phase II to commercial.

### PRE-LAUNCH

Niche innovative solutions to accelerate development and access to new medicines

**128**

COUNTRIES SUPPLIED  
IN LAST 3 YEARS

**25,000+**


HCP CUSTOMERS\*

**500+**

PHARMA CLIENTS

### POST-LAUNCH

Global platform to enable broader access to critical medicines in unlicensed and licensed markets



## SERVICES

## PRODUCTS

\*HCPs as customers indicates the number of registered users on Cliinport